Clinical trials
Every registered trial of Tesamorelin
23 studies, 3 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Tesamorelin has a real but limited body of human research.
- 23 registered studies in total.
- 3 are still enrolling people, so this is active research, not just history.
What kind of research
- 20 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 1,503 people took part in those.
- A further 3 studies only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 4 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 9 have published results in the medical literature that anyone can read.
- The research spans 7 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 23 of 23 trials for Tesamorelin.
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
Hudson Biotech
Metabolic Associated Steatotic Liver Disease · Nonalcoholic Steatohepatitis · Hepatic Steatosis
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Massachusetts General Hospital
HIV-1-infection · Frailty · Impaired Physical Function · Abdominal Obesity
Growth Hormone Dynamics and Cardiac Steatosis in HIV
Massachusetts General Hospital
Human Immunodeficiency Virus · Lipodystrophy · Cardiac Disease
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease · Obesity · Obesity, Abdominal · Liver Fat
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Johns Hopkins University
Peripheral Nerve Injuries
Body Composition and Adipose Tissue in HIV
Columbia University
HIV Lipodystrophy Syndrome · Growth Hormone Deficiency · Body Composition
The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment
The University of Texas Medical Branch, Galveston
Mild Cognitive Impairment
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
University of California, San Diego
Mild Cognitive Impairment
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
National Institute of Nursing Research (NINR)
Sleep Disorder · Traumatic Brain Injury
Tesamorelin Effects on Liver Fat and Histology in HIV
Massachusetts General Hospital
Human Immunodeficiency Virus (HIV) · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis (NASH)
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
Massachusetts General Hospital
Abdominal Obesity
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®
Theratechnologies
HIV
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
Theratechnologies
Diabetic Retinopathy · HIV
Egrifta Replacement and Sleep Disordered Breathing
Johns Hopkins University
Lipodystrophy
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
Theratechnologies
Chronic Obstructive Pulmonary Disease (COPD)
Effects of Growth Hormone Releasing Hormone in HIV
Massachusetts General Hospital
HIV · HIV Lipodystrophy
Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men
Massachusetts General Hospital
Healthy Volunteers
Effects of Short-term Growth Hormone in HIV-infected Patients
Massachusetts General Hospital
HIV Lipodystrophy
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese
Massachusetts General Hospital
Abdominal Obesity · Growth Hormone Deficiency
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
Theratechnologies
HIV
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Theratechnologies
Lipodystrophy · HIV Infections
TH9507 in Patients With HIV-Associated Lipodystrophy
Theratechnologies
HIV Infections · Lipodystrophy
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
Theratechnologies
Type 2 Diabetes
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Tesamorelin is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.